Literature DB >> 19727272

Short-acting versus Long-acting Medications for the Treatment of ADHD.

Elisa Cascade1, Amir H Kalali, Richard H Weisler.   

Abstract

Primary care physicians, pediatricians, and psychiatrists account for approximately 80 percent of attention deficit hyperactivity disorder (ADHD) treatments prescribed in the United States. Selection of short-acting versus long-acting ADHD treatment varies by specialty with long-acting agents representing 56 percent of primary care prescriptions, 64 percent of psychiatrist prescriptions, and 79 percent of pediatric prescriptions. There appears to be a correlation between short-acting versus long-acting treatment selection and age, with long-acting agents accounting for 78 percent of prescriptions for pediatric patients (age 0-17) but only 49 percent of prescriptions for adults (patients aged 18+). A discussion of data is included.

Entities:  

Keywords:  ADHD medication; attention deficit hyperactivity disorder; long-acting formulation; prescription; short-acting formulation; stimulant

Year:  2008        PMID: 19727272      PMCID: PMC2695738     

Source DB:  PubMed          Journal:  Psychiatry (Edgmont)        ISSN: 1550-5952


  10 in total

1.  Comparison of acute behavioral effects of sustained-release and immediate-release methylphenidate.

Authors:  S H Kollins; C R Rush; P J Pazzaglia; J A Ali
Journal:  Exp Clin Psychopharmacol       Date:  1998-11       Impact factor: 3.157

2.  Illicit use of specific prescription stimulants among college students: prevalence, motives, and routes of administration.

Authors:  Christian J Teter; Sean Esteban McCabe; Kristy LaGrange; James A Cranford; Carol J Boyd
Journal:  Pharmacotherapy       Date:  2006-10       Impact factor: 4.705

3.  Characteristics of adolescents and young adults with ADHD who divert or misuse their prescribed medications.

Authors:  Timothy E Wilens; Martin Gignac; Allison Swezey; Michael C Monuteaux; Joseph Biederman
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2006-04       Impact factor: 8.829

4.  Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning.

Authors:  Russell A Barkley; Kevin R Murphy; George I Dupaul; Tracie Bush
Journal:  J Int Neuropsychol Soc       Date:  2002-07       Impact factor: 2.892

Review 5.  A qualitative review of issues arising in the use of psycho-stimulant medications in patients with ADHD and co-morbid substance use disorders.

Authors:  Scott H Kollins
Journal:  Curr Med Res Opin       Date:  2008-04-01       Impact factor: 2.580

6.  Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies.

Authors:  James Swanson; Suneel Gupta; Andrew Lam; Ira Shoulson; Marc Lerner; Nishit Modi; Elizabeth Lindemulder; Sharon Wigal
Journal:  Arch Gen Psychiatry       Date:  2003-02

7.  Methylphenidate and dextroamphetamine abuse in substance-abusing adolescents.

Authors:  Robert J Williams; Leslie A Goodale; Michele A Shay-Fiddler; Susan P Gloster; Samuel Y Chang
Journal:  Am J Addict       Date:  2004 Jul-Sep

8.  PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short- and long-acting oral methylphenidate.

Authors:  Thomas J Spencer; Joseph Biederman; Patrick E Ciccone; Bertha K Madras; Darin D Dougherty; Ali A Bonab; Elijahu Livni; Dolly A Parasrampuria; Alan J Fischman
Journal:  Am J Psychiatry       Date:  2006-03       Impact factor: 18.112

9.  Human pharmacology of intravenous lisdexamfetamine dimesylate: abuse liability in adult stimulant abusers.

Authors:  D R Jasinski; S Krishnan
Journal:  J Psychopharmacol       Date:  2008-07-17       Impact factor: 4.153

Review 10.  Review of long-acting stimulants in the treatment of attention deficit hyperactivity disorder.

Authors:  Richard H Weisler
Journal:  Expert Opin Pharmacother       Date:  2007-04       Impact factor: 3.889

  10 in total
  12 in total

1.  A randomized, double-blind, cross-over, phase IV trial of oros-methylphenidate (CONCERTA(®)) and generic novo-methylphenidate ER-C (NOVO-generic).

Authors:  Angelo Fallu; Farida Dabouz; Melissa Furtado; Leena Anand; Martin A Katzman
Journal:  Ther Adv Psychopharmacol       Date:  2016-05-01

2.  Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.

Authors:  Richard H Weisler; Ann C Childress
Journal:  Prim Care Companion CNS Disord       Date:  2011

3.  Update on optimal use of lisdexamfetamine in the treatment of ADHD.

Authors:  Vishal Madaan; Venkata Kolli; Durga P Bestha; Manan J Shah
Journal:  Neuropsychiatr Dis Treat       Date:  2013-07-22       Impact factor: 2.570

Review 4.  Advances in understanding and treating ADHD.

Authors:  Kevin M Antshel; Teresa M Hargrave; Mihai Simonescu; Prashant Kaul; Kaitlin Hendricks; Stephen V Faraone
Journal:  BMC Med       Date:  2011-06-10       Impact factor: 8.775

Review 5.  Adherence, persistence, and medication discontinuation in patients with attention-deficit/hyperactivity disorder - a systematic literature review.

Authors:  Kavita Gajria; Mei Lu; Vanja Sikirica; Peter Greven; Yichen Zhong; Paige Qin; Jipan Xie
Journal:  Neuropsychiatr Dis Treat       Date:  2014-08-22       Impact factor: 2.570

Review 6.  Methylphenidate extended-release oral suspension for the treatment of attention-deficit/hyperactivity disorder: a practical guide for pharmacists.

Authors:  Joshua Caballero; Edress H Darsey; Faith Walters; Heidi W Belden
Journal:  Integr Pharm Res Pract       Date:  2017-10-17

7.  Adult ADHD: Questioning Diagnosis and Treatment in a Patient with Multiple Psychiatric Comorbidities.

Authors:  Robert Karoly Chu; Tea Rosic; Zainab Samaan
Journal:  Case Rep Psychiatry       Date:  2017-06-11

8.  Effect of lisdexamfetamine dimesylate on sleep in adults with attention-deficit/hyperactivity disorder.

Authors:  Lenard A Adler; David Goodman; Richard Weisler; Mohamed Hamdani; Thomas Roth
Journal:  Behav Brain Funct       Date:  2009-08-03       Impact factor: 3.759

9.  Once-daily medications for the pharmacological management of ADHD in adults.

Authors:  Oleg V Tcheremissine; Lori M Lieving
Journal:  Ther Clin Risk Manag       Date:  2009-05-20       Impact factor: 2.423

10.  Attention deficit hyperactivity disorder and athletes.

Authors:  Russell D White; George D Harris; Margaret E Gibson
Journal:  Sports Health       Date:  2014-03       Impact factor: 3.843

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.